Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Elena Pallari receives $25,000 for proposal for innovation in clinical research assessment LONDON, Sept. 13, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today named Elena Pallari, Department of Clinical Trials and Methodology, University College London, U.K., as the recipient of the 2021 Eugene Garfield Award for Innovation in Citation Analysis.

Clarivate Announces Winner of Eugene Garfield Award 2021

LONDON, Sept. 10, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate") announced today that affiliated funds of Onex Corporation ("Onex") (TSX: ONEX) and Baring Private Equity Asia Group Ltd ("BPEA") (together, the "Selling Shareholders") have priced an underwritten public offering of an aggregate of 25,000,000 ordinary shares of the Company.

Clarivate Announces Pricing of Secondary Ordinary Share Offering

LONDON, Sept. 9, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate") announced today that affiliated funds of Onex Corporation ("Onex") (TSX: ONEX) and Baring Private Equity Asia Group Ltd ("BPEA") (together, the "Selling Shareholders") intend to offer an aggregate of 25,000,000 ordinary shares of the Company in an underwritten public offering, subject to market conditions.

Clarivate Announces Secondary Ordinary Share Offering

LONDON, Sept. 8, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jerre Stead, Executive Chairman and Chief Executive Officer, and Richard Hanks, Chief Financial Officer, will present at the Barclays Global Financial Services Conference on Wednesday, September 15, 2021 at 11:15 AM Eastern Time.

Clarivate to Present at the Barclays Global Financial Services Conference on September 15, 2021

LONDON, Aug. 19, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced the settlement of the previously announced private offers to exchange (the "Exchange Offers"), by Clarivate Science Holdings Corporation, its indirect wholly owned subsidiary ("CSHC"), any and all of its outstanding 3.875% Senior Secured Notes due 2028 (the "Old Secured Notes") and 4.875% Senior Notes due 2029 (the "Old Unsecured Notes" and, together with the Old Secured Notes, the "Old Notes") for two new series of CSHC's senior notes (collectively, the "New Notes"). On August 19, 2021 (the "Settlement Date"), CSHC accepted tenders from holders of $921,177,000 aggregate principal amount of Old Secured Notes and $921,399,000 aggregate principal amount of Old Unsecured Notes.

Clarivate Announces Settlement of Private Exchange Offers and Redemption of Untendered Notes

LONDON, Aug. 16, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced the expiration of two separate private offers to exchange (the "Exchange Offers"), by Clarivate Science Holdings Corporation, its indirect wholly owned subsidiary ("CSHC"), any and all of the outstanding notes listed in the table below (collectively, the "Old Notes") for two new series of CSHC's senior notes (collectively, the "New Notes"). The Old Notes, which contain a provision requiring Clarivate to redeem such notes if its previously announced acquisition of ProQuest has not been consummated on or before November 8, 2021, are being exchanged for New Notes which extend such end date to April 29, 2022, among other changes, on the terms and subject to the conditions set forth in the Offering Memorandum dated August 9, 2021 (the "Offering Memorandum" and, together with the eligibility letter and the notice of guaranteed delivery, the "Exchange Offer Documents").

Clarivate Announces Expiration of its Private Exchange Offers for Two Series of Notes

LONDON, Aug. 9, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Clarivate Science Holdings Corporation, its indirect wholly owned subsidiary ("CSHC"), has commenced a transaction to exchange two series of its outstanding notes as detailed below. In relation to Clarivate's previously announced acquisition (the "Acquisition") of ProQuest ("ProQuest"), on July 28, 2021, Clarivate received a second request for documents and other information from the Federal Trade Commission (the "FTC"), which is reviewing the Acquisition pursuant to authority under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Clarivate Announces Private Exchange Offers for Two Series of Notes Open to Certain Investors

Clarivate PLC (NYSE: CLVT) acquired Bioinfogate, an analytics solutions provider in the life sciences and producer of the OFF-X portal.  The financial terms of the transaction remain undisclosed.

Clarivate Acquires Bioinfogate For Undisclosed Terms To Expand Drug R&D Intelligence

Expanding and integrating drug toxicity data and translational safety intelligence from OFF-X into all aspects of the life science cycle, allowing customers to make more informed decisions  LONDON, Aug. 4, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that it has acquired Bioinfogate, a leading provider of analytics solutions in the life sciences and producer of the OFF-X™ portal. Financial terms of the transaction were not disclosed.

Clarivate Acquires Bioinfogate, Reinforcing Position as Premier Provider of End-to-End Research Intelligence Solutions for Life Sciences

LONDON, Aug. 3, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that its Board of Directors has approved the purchase of up to $250 million of the Company's ordinary shares through open-market purchases, to be executed through October 31, 2021. "Our Board is confident in both our short and long-term growth prospects and believes repurchasing our shares represents an attractive investment opportunity," said Jerre Stead, Executive Chairman and CEO.

Clarivate Announces $250 Million Share Repurchase Program

Clarivate Plc (CLVT) CEO Jerre Stead on Q2 2021 Results - Earnings Call Transcript

Clarivate PLC (NYSE: CLVT) reported second-quarter revenue growth of 61.4% year-over-year to $447 million (up 5% on an organic basis), beating the consensus of $435.24 million. Revenues from Subscription increased 12.5% Y/Y to $243.6 million, driven by the acquisition of CPA Global, Re-occurring revenues were $113.7 million, and Transactional increased 48.7% Y/Y to $89.8 million.

Clarivate Stock Falls After In-line Q2 Earnings, Trimmed FY21 EPS Outlook

Clarivate PLC (CLVT) delivered earnings and revenue surprises of -5.56% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Clarivate PLC (CLVT) Q2 Earnings Lag Estimates

Shares of Clarivate (NYSE:CLVT) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share decreased 5.56% year over year to $0.17, which were in line with the estimate of $0.17.

Clarivate: Q2 Earnings Insights

LONDON, July 29, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in providing trusted information and insights to accelerate the pace of innovation, today reported results for the second quarter ended June 30, 2021. Second Quarter 2021 Financial Highlights Revenues of $445.6 million and Adjusted Revenues(1) of $447.0 million, increased 59% and 57%, respectively, at constant currency Organic revenues(1), which exclude the impact of acquisitions and divestitures, increased 5%, at constant currency Net loss of $82.2 million increased 225%; Adjusted Net Income(1) of $110.0 million increased 58% Net loss per diluted share of $(0.13) increased $0.06; Adjusted Income per diluted share(1) (EPS) of $0.17 decreased $0.01 due to a 63% increase in the weighted average ordinary shares outstanding driven primarily by the CPA Global acquisition and the Company's 1H 2020 primary and secondary offerings, which have now been outstanding for a full period Adjusted EBITDA(1) of $189.0 million increased 89% and Adjusted EBITDA Margin(1) of 42% increased 610 basis points First Half 2021 Financial Highlights Revenue of $874.1 million and Adjusted Revenue(1) of $878.5 million increased 66% and 65%, respectively, at constant currency Organic revenues([1]), which exclude the impact of acquisitions and divestitures, increased 6%, at constant currency Net loss of $106.2 million decreased 32%; Adjusted Net Income(1) of $198.4 million increased 109% Net loss per diluted share of $(0.17) decreased 60% or $(0.26); Adjusted Income per diluted share(1) (EPS) of $0.31 increased 24% or $0.06 Adjusted EBITDA(1) of $353.8 million increased 98% and Adjusted EBITDA Margin(1) of 40% increased 600 basis points Cash Flow from Operations increased $154 million to $262 million; Adjusted Free Cash Flow(1) increased $138.9 million to $258.5 million   ________________________________ 1 Represents a Non-GAAP measure.

Clarivate Reports Second Quarter 2021 Results

Clarivate PLC (CLVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clarivate PLC (CLVT) Q2 Earnings Preview: What's in the Cards?

LONDON, July 21, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of the Cortellis Supply Chain Network™, a part of the Cortellis suite of life science intelligence solutions. The solution supports generics companies, Active Pharmaceutical Ingredients (API) manufacturers, fine chemical manufacturers, excipient manufacturers, raw materials suppliers, and biopharma in their pursuit to maintain a steady supply chain -- ultimately making therapies easily accessible to all patients.

Clarivate Introduces Cortellis Supply Chain Network™, a Revolutionary Digital Partnering Solution

CAMPBELL, Calif., July 14, 2021 /PRNewswire/ -- The Society for Information Display (SID) has announced that SID's flagship publication, the Journal of the Society for Information Display (JSID), now has an Impact Factor of 2.140, a substantial increase from previous years.

SID Reports Significant 'Impact Factor' Increase for Flagship Publication

Reducing manual data entry efforts to help customers save time and increase data quality LONDON, July 14, 2021 /PRNewswire/ --  Clarivate Plc  (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the integration of its trademark research and protection solutions powered by CompuMark™ into IPfolio™ and FoundationIP™, IP management software (IPMS) solutions for corporations and law firms. This integration is part of a long-term strategy by Clarivate to remove friction from IP management processes by connecting the IP ecosystem.

Clarivate Integrates Trademark Solutions to Unlock the Full Value of Customers' IP

State of innovation in electric vehicles, design challenges and opportunities uncovered by combining the power of unified IP with global research data insights LONDON, July 8, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released a new report, The road ahead: sustainable vehicles today and in the future , that reveals the state of innovation in electric vehicles (EVs), the changing competitive landscape and geographic trends.  Despite impressive strides in innovation in the last two decades, vehicle charge time and battery capacity are unsolved, critical design issues and overcoming them is vital to unlocking the market potential for electric vehicles.

New Clarivate Report Identifies Battery Capacity and Charging Technologies as Key to Accelerating Electric Vehicle Adoption

LONDON, July 7, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today unveiled significant enhancements to the Web of Science™ offering researchers a highly dynamic, personal and indispensable research assistant through a host of new features and a redesigned user interface. The Web of Science is the world's most trusted publisher-independent global citation database, home to an unrivalled breadth of world-class research literature linked to a rigorously selected core of journals.

Clarivate Launches New Web of Science to Accelerate the Pace of Research and Discovery

LONDON, July 6, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced important changes to its senior leadership team and is pleased to welcome two new executives to the company.  Steen Lomholt-Thomsen will join on August 2 in the newly created position of Chief Revenue Officer and Jaspal (Jas) Chahal joins today as Chief Legal Officer and General Counsel.

Clarivate Announces Changes to Executive Leadership Team and Adds Chief Revenue Officer

LONDON, July 2, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today it will report its financial results for the second quarter 2021 before the market opens on Thursday, July 29. The press release and earnings supplement, with accompanying financial information, will be posted on the Clarivate investor website at https://ir.clarivate.com.

Clarivate to Report Second Quarter 2021 Results on July 29, 2021

2021 launch delivers expanded content, new Journal Citation Indicator and revamped user interface LONDON , June 30, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2021 update to its annual Journal Citation Reports (JCR)™. The annual JCR release enables the research community to evaluate the world's high-quality academic journals using a range of indicators, descriptive data and visualizations.

Clarivate Releases Journal Citation Reports, Naming the World's Leading Journals

Atlanticus Holdings

Bank of Hawaii

Carlyle Group

CMS Energy

Great Elm Capital

Gladstone Commercial

Gladstone Commercial Corp 7 1/2 % Cum Red Pfd Shs Series B

Harbor Custom Development, Inc.

Public Storage

Prospect Capital

Ready Capital Corp

Sachem Capital

Presidio Property Trust

TPG RE Finance Trust

As June 2021 comes to a close, we look back at the new preferred stocks and ETDs introduced during the month, offering annual yields ranging from 4% to 9.375%.

News for Clarivate Plc Stock (CLVT)